Moors & Cabot Inc. trimmed its position in shares of VanEck Biotech ETF (NASDAQ:BBH – Free Report) by 86.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,205 shares of the company’s stock after selling 14,608 shares during the quarter. Moors & Cabot Inc. owned approximately 0.11% of VanEck Biotech ETF worth $539,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in the company. Allworth Financial LP acquired a new position in shares of VanEck Biotech ETF in the 3rd quarter worth approximately $104,000. Fifth Third Bancorp bought a new stake in VanEck Biotech ETF during the 3rd quarter worth approximately $165,000. Kestra Advisory Services LLC acquired a new stake in VanEck Biotech ETF during the 3rd quarter valued at $788,000. Commonwealth Equity Services LLC acquired a new stake in VanEck Biotech ETF during the 3rd quarter valued at $1,009,000. Finally, Caldwell Trust Co acquired a new stake in VanEck Biotech ETF during the 3rd quarter valued at $47,000. 32.05% of the stock is owned by institutional investors.
VanEck Biotech ETF Trading Down 0.4%
Shares of BBH opened at $247.78 on Wednesday. The stock has a fifty day moving average price of $244.49 and a two-hundred day moving average price of $210.30. VanEck Biotech ETF has a 52-week low of $179.25 and a 52-week high of $263.74.
About VanEck Biotech ETF
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
Featured Stories
- Five stocks we like better than VanEck Biotech ETF
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
